Horizon hailed as 'world's leading gene-editing' company after acquiring Sage
- Horizon is paying up to $48 million for Sage Labs, considered "a world leader in the generation of advanced in vivo transgenic disease models for use in preclinical research," according to PharmaTimes.
- Horizon recently completed an $8 million acquisition of CombinatorRx, which provides services related to translational genomics and personalized medicine research .
- Sage comes armed with sales forces in both the EU and the U.S.
Have a biological question that needs to be answered? If the goal is to find an in vivo and/or in vitro solution to your question, Horizon is now the go-to destination for people around the world -- especially for researchers and scientists.
Prior to becoming an independent company in 2013, Sage was part of Sigma-Aldrich. It has 50 employees, a large sales force that spans multiple continents, and 43,000 square feet of work space. By investing $16 million in cash and $32 million in shares, Horizon has fortified its place as a leader in the field of personalized medicine and genomics.